8
Due to this inflation, these results must be interpreted with caution. 2 3 9
Association between DNA methylation and cardiovascular outcomes: candidate-genes 2 4 0 strategy 2 4 1
A. Analyses with prevalent data 2 4 2
This meta-analysis included 1,400 CpGs. Five and one CpGs were related to AMI and CHD 2 4 3 (p <3.571·10 -5 ) in models 1 and 2, respectively, but none in model 3. In total, five unique 2 4 4
CpGs were related to AMI and CHD, and their magnitude of association were similar in the 2 4 5 three models (Additional File 6: Figure S6 , and Additional File 7: Table S8 ). These CpGs 2 4 6 were located in four different genes and one intergenic region. 2 4 7
The most interesting results (p <3.571·10 -5 ) in each individual study are shown in Additional 2 4 8
File 7: Tables S9-S10. 2 4 9 B. Analyses with incident CHD and CVD events 2 5 0
We included 1,539 CpGs in this analysis. No CpG was associated with CHD in any model. 2 5 1
Conversely, two and one CpGs were related to CVD (p <3.249·10 -5 ) in models 1 and 2, 2 5 2 respectively, but none in model 3. In total, three differentially methylated CpGs were related 1 1 to CVD. The effect sizes of the associations betweenthe three CpGs and CVD were similar in 2 5 4 the three models (Additional File 6: Figure S7 , and Additional File 7: Table S11 ). They were 2 5 5 located within the genes AHRR and CPT1A and one intergenic region. Two of these three 2 5 6
CpGs were also identified in the EWAS analysis with prevalent CHD (cg21566642 and 2 5 7 cg05575921). 2 5 8
We did not observe any significant association (p <3.249·10 -5 ) between any CpG and 2 5 9 incident cardiovascular events in the individual analysis of each study. 2 6 0 Association between the identified CpGs and CVRFs 2 6 1 Table 4 shows the associations observed between the identified CpGs and classical CVRFs: 2 6 2 smoking status, body mass index (BMI), systolic/diastolic blood pressure, and levels of 2 6 3 glucose, triglycerides, total cholesterol, HDL-C and cholesterol transported in low-density 2 6 4 lipoproteins (LDL-C). Six CpGs of the 13 identified in the EWAS strategy (Additional file 8: 2 6 5 Table S12 ) and one of the six found in the candidate-gene strategy (Additional file 8: Table  2 6 6 S13) were not related to any CVRF. 2 6 7
Association between MRS and incidence of CHD and CVD 2 6 8
The associations between MRS and the incidence of clinical coronary (n=94) and 2 6 9 cardiovascular (n=222) events in the Framingham population are shown in Table 5 . The 2 7 0 median and interquartile range of the follow-up periods for CVD and CHD incidence were 2 7 1 7. 67 (5.45, 9.89) and 7.87 (6.50, 9.25 ) years, respectively. Only the MRS for incident CVD 2 7 2 events, including the CpGs identified in both the EWAS and candidate-gene strategies, were 2 7 3 associated with higher CVR independently of the classical CVRFs. The addition of any MRS to the Framingham risk function did not improve its capacity to 2 7 5 discriminate either CVD or CHD in the Framingham cohort. Similarly, no increase in NRI was 2 7 6 observed after including the MRS in the CVR function (Table 5 ).
7 7
Causality of the associations between DNA methylation and cardiovascular outcomes 2 7 8
We were able to assess causality of the association between CHD and two of the identified 2 7 9
CpGs, cg21566642 (located in an intergenic region in chromosome 2) and cg03636183 2 8 0 (located within F2RL3). However, applying the criteria described in the Methods section, we identified only one genetic variant associated with each of these CpGs. Therefore, only the 2 8 2
Wald ratio method could be performed in the MR-Base web-app, and none of the 2 8 3 associations was significant (Additional file 9: Table S14 ). We have identified 17 methylation loci associated with CHD and CVD, 10 of them newly 2 8 7
reported. Approximately 2/3 of these CpG sites were also related to traditional CVRFs, 2 8 8 supporting the role of smoking and lipids in the development of these diseases, while 1/3 of 2 8 9
the CpGs were not related to classical CVRFs, suggesting a key role of inflammation 2 9 0 (Additional file 10: Table S15 ). We further constructed MRS and validated the association of 2 9 1 some of these scores with CVD incidence independently of the traditional CVRFs. However, 2 9 2 we did not observe an improvement of the predictive capacity of cardiovascular events when 2 9 3 we included those risk scores in a CVR function. Additionally, our results about the causality 2 9 4 of the association between the identified CpGs and CHD were not conclusive. 2 9 5
CpG sites consistently related to prevalent and incident CVD events 2 9 6
Two CpGs, cg21566642 and cg05575921, were significantly related to both prevalent CHD 2 9 7 and incident CVD. cg21566642 maps to an intergenic region in chromosome 2. cg05575921 2 9 8 annotates to AHRR. To our knowledge, these CpGs were not associated with cardiovascular 2 9 9 events in previous EWAS reports. Both CpGs were highly and inversely associated with 3 0 0 smoking, which is supported by previous EWAS [29, 30] . We have also previously reported 3 0 1 both CpG sites as related to CVR independent of age [9] . cg05575921 was further 3 0 2 associated directly with HDL-C and inversely with triglyceride levels in our study. This CpG 3 0 3
has been related to all-cause mortality in a recent EWAS report [31] and was associated with 3 0 4
both CHD prevalence and incidence in a candidate gene study [32] . 3 0 5
Moreover, other four CpGs showed consistent association across the different outcomes of 3 0 6
interest: cg06500161, cg21429551, cg19390658 and cg00574958. cg06500161 maps to 3 0 7 ABCG1, which encodes a transporter involved in lipid homeostasis [33, 34] . It has been 3 0 8 previously related to CHD. Pfeiffer et al found this CpG in an EWAS assessment of lipid 3 0 9 profile, and reported its association with AMI in their discovery population but not in their 3 1 0 replication sample [35] . Hedman et al found another CpG located within ABCG1 that was 3 1 1 related to lipids, as associated with incident CHD events [36] . Conversely, Campanella et al 3 1 2 assessed the association between AMI and adiposity-related CpGs from their study, but did 3 1 3 not associate cg06500161 with this outcome. We further found cg06500161 to be strongly 3 1 4
and directly related to BMI and levels of triglycerides and inversely associated with HDL-C (p 3 1 5 <2.2·10 -16 ). These associations have been previously observed in other studies [35] [36] [37] [38] . 3 1 6
cg06500161 methylation level has also been associated with ceramides and sphingomyelins 3 1 7 levels [36], whose role in atherosclerosis and CHD has been reported [39, 40] . 3 1 8 cg21429551 and cg19390658 map to GARS, which encodes the ligase glycyl-tRNA 3 1 9
synthetase. These CpGs were associated with smoking, BMI, triglycerides and HDL-C levels 3 2 0 in our study and in previous reports [36, 49, 50] . Two previous candidate gene studies 3 2 1 including both CpGs or cg21429551 alone have shown negative results regarding their 3 2 2 association with CHD [32, 36] . cg00574958, is located within CPT1A, which encodes an 3 2 3 enzyme that regulates mitochondrial fatty acid oxidation [51] . It was positively associated 3 2 4
with HDL-C levels and inversely associated with BMI and blood pressure, glucose and 3 2 5 triglycerides levels. These findings are consistent with previous studies [9, 36, 38, [52] [53] [54] . 3 2 6
Genetic variants in CPTA1 have also been associated with calcified atherosclerotic plaque in 3 2 7 coronary artery [55]. 3 2 8
All these results highlight the relevance of smoking (AHRR) and lipid metabolism (ABCG1, 3 2 9 GARS and CPTA1) to atherosclerosis and CHD. 3 3 0
Other CpG sites related to prevalent CHD events 3 3 1
Six additional CpGs were related to prevalent cases of CHD. One of them, 3 3 2 cg03636183, which maps to F2RL3, is widely reported to be associated with smoking [17], 3 3 3 consistent with our findings. It is also related to all-cause and cardiovascular mortality 3 3 4
[31,41,42]. 3 3 5
Three additional CpGs of the six were also associated with CVRFs but their association with 3 3 6 CHD has not been previously reported. cg00076653 (located within C1QTNF7) was directly 3 3 7 1 4 associated with glucose levels. C1QTNF7 encodes a member of the CTRP family of 3 3 8 adipokines related to metabolic dysfunction in the context of obesity [43] . cg11643285 and 3 3 9 cg17238319 (both mapping to RFTN1) were associated with total and LDL cholesterol. 3 4 0
Finally, cg14597545 and cg19314882, annotated to ADPGK and DSCAML1, respectively, 3 4 1 were associated with prevalent CHD but not with CVRFs. Previous studies have found that 3 4 2 cg14597545 is differentially methylated in the offspring of mothers with preeclampsia [44] 3 4 3 cg19314882 is related to air pollution [45] . 3 4 4
These six CpGs were not related to incident events, calling into question the temporal 3 4 5 sequence of events and suggesting that these methylation signatures could be a 3 4 6 consequence of the coronary event instead of a cause. 3 4 7
Additional CpG sites related to incident CHD or CVD events 3 4 8
Three CpGs (cg19893751, cg09165129 and cg07817505) were related to incident cases of 3 4 9 CHD in the EWAS strategy. Neither was related to any CVRF. These three CpGs must be 3 5 0 considered with caution as we could not correct the genomic inflation of the results in the 3 5 1 WHI sample. Further information about these CpGs is provided in Additional file 10: Table  3 5 2 S15. 3 5 3
Two additional CpGs were related to CVD incident events: cg08122652 and cg25103337. 3 5 4 cg08122652 is located within PARP9/DTX3L. Increased expression of PARP9/DTX3L gene 3 5 5 complex boosts immune response [46] . PARP9 is involved in the regulation of macrophage 3 5 6 activation via pro-inflammatory IFN-γ signalling, which underlies the role of inflammation in 3 5 7 the pathogenesis of CHD [47] . Interestingly, a recent study related methylation at this CpG to 3 5 8 lower risk of incident CHD, consistent with our findings in incident CVD [48] . cg25103337, 3 5 9 mapping to H6PD, which encodes one enzyme involved in the glucose metabolism (pentose 3 6 0 phosphate pathway), was not related to any CVRF. Over-activation of this pathway was 3 6 1 reported to cause the vascular inflammation associated to hyperglycaemia [56] . Experimental 3 6 2 and observational studies have also reported an inverse relation between deficiency of the 3 6 3 enzyme and atherosclerosis and CHD [57, 58] . Overall, these evidences also suggest the 3 6 4 relevance of inflammation to atherosclerosis and CHD.
1 5
Methylation risk scores as predictive CVD biomarkers 3 6 6
To assess the value of the identified CpGs as CVR biomarkers, we followed the AHA 3 6 7
recommendations [59] . The risk scores based on CpGs associated with CVD incident cases 3 6 8 were also associated with the incidence of CVD events in the FOS. However, we did not 3 6 9
observe an improvement in the predictive capacity of the Framingham risk function when 3 7 0
including any of the MRSs. This highlights the challenges of CVR prediction and novel 3 7 1 biomarkers discovery, as well as the complex molecular network underlying CVD. 3 7 2
Causality of the associations between methylation loci and cardiovascular outcomes 3 7 3
MR studies based on public meQTLs could only be performed on the associations of 3 7 4 cg21566642 and cg03636183 with AMI and CHD. Although a non-causal relationship was 3 7 5
suggested, this must be interpreted with caution as only one genetic variable was used as 3 7 6 genetic instrument. However, the association between CVRFs and some of the reported 3 7 7
CpGs suggest that methylation at these loci might occur prior to a CVD event. The main strength of our study is that we included three independent populations and used 3 8 0 two complementary strategies (hypothesis-free and hypothesis-based) to unravel methylation 3 8 1 patterns related to cardiovascular events. We further assessed the relationships in both 3 8 2 prevalent and incident cases. 3 8 3
On the one hand, we are aware of several limitations regarding the study design and the 3 8 4 differences between the samples. First, we did not have access to information about AMI 3 8 5 events in all populations and so could not compare methylation changes related to this 3 8 6 specific CHD outcome. Second, our study is based on populations of European origin and 3 8 7
has intrinsic EWAS limitations such as the type of sample used or the population size. On the other hand, some analytical and technical limitations were also observed. First, one 3 8 9 third of the CpGs analysed in the REGICOR population could not be assessed in the FOS 3 9 0 population as the methylation arrays differed in the number of interrogated CpGs (EPIC VS 3 9 1 450k, respectively). Second, we could not reduce the inflation in the CHD results of the WHI 3 9 2 sample; however, the two CpGs reported from this approach were also related to CHD in the 3 9 3 FOS population. Last, we cannot infer causality in the approach with prevalent cases, since 3 9 4 changes in methylation could have occurred either prior to the event or as a consequence of 3 9 5 the acute phase and disease management. We aimed to perform Mendelian randomization 3 9 6 studies of the association between the identified CpGs and cardiovascular events, but 3 9 7 available meQTL datasets are still limited. 3 9 8
Conclusion 3 9 9
Our study provides novel findings on DNA methylation loci related to the risk of CHD and We designed two strategies: epigenome-wide and candidate-gene association studies. In both strategies, we used three independent corresponding combinations. Those CpGs significant after correcting for multiple comparisons were analysed in association with classical 4 1 4 cardiovascular risk factors (CVRFs). We also evaluated the causality of their association with acute myocardial infarction (MI) and coronary 4 1 5 heart disease (CHD). Finally, we constructed risk scores based on those CpGs (MRSs) to assess their predictive value of incident 4 1 6 cardiovascular events and to evaluate the predictive capacity of a cardiovascular risk (CVR) function including these MRSs. 4 1 7
Figure 2. Forest plot of the associations between the significant CpGs (p <1.21·10 -7 )
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